Prof Terpos speaks to ecancer about the real-world evidence of the use of approved carfilzomib regimens previously exposed or refractory to lenalidomide: updated results from a prospective observational study.
This study was presented at ASH 2020.
In this interview Prof Terpos initially explains what this study was about. He says that with approvals of lenalidomide based therapy for the treatment of transplant ineligible patients with newly diagnosed multiple myeloma, and for patients receiving maintenance following transplant, there is an increasing use of lenalidomide as induction and maintenance therapy.
As a result, treatment options for patients who become lenalidomide-refractory has become an emerging critical challenge.
He says that this study updates results from a large real-life cohort of patients with refractory status, who received approved lenalidomide and dexamethasone regimens previously.
Prof Terpos then goes on to explain the key results form this study and what these results can mean for the future treatment of multiple myeloma patients.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.